

For Immediate Release
For Further Information Contact:
Andrew Fisher at (301) 608-9292
Email: Afisher@unither.com

**UNITED THERAPEUTICS GRANTED MAXIMUM
FIVE-YEAR PATENT TERM EXTENSION FOR REMODULIN®**

Silver Spring, MD, February 23, 2005: United Therapeutics Corporation (NASDAQ: UTHR) today announced that it has been granted a five-year patent term extension by the United States Patent and Trademark Office for its patent covering the method of treating pulmonary hypertension using Remodulin. U.S. Patent Number 5,153,222, titled "Method of Treating Pulmonary Hypertension with Benzidine Prostaglandins," was originally scheduled to expire on October 6, 2009. It will now expire on October 6, 2014. The five-year Hatch-Waxman Act extension is the maximum extension allowed under 35 U.S.C. §156.

United Therapeutics is a biotechnology company focused on the development and commercialization of unique products for patients with chronic and life-threatening cardiovascular, cancer and infectious diseases.

* * *